MarginsXMarginsX
Home › Markets › Health Care › GYRE

Gyre Therapeutics Inc. (GYRE)

GYRE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.39
+1.86% on the day
Market cap
$506.3M
Small cap
Revenue · 2025
$116.6M
+10.2% on 2024
Net income · 2025
$9.9M
8.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/0001193125-26-106251-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGYRE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2006
SEC CIK0001124105
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$116.6M
Net income$9.9M
Operating income$11.5M
Net margin8.5%
Operating margin9.9%
Revenue growth+10.2%
Cash$37.1M
Total assets$166.1M
P/E (computed)51.2×
P/S (computed)4.3×

Warning signs

Cash runway
78.9 months
$41.6M cash at September 30, 2026
Share count, 1 year
+19.7%
2025-10-31 to 2026-11-01 · +4454.8% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$953K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$41.6M cash; operating cash flow -$1.6M a quarter.Report 2026-09-30
Shares outstanding115,321,017 (2026-11-01); 96,333,157 a year earlier; 37,978,142 three years earlier. 3y figure adjusted for splits (1-for-15 overall).Cover page 2026-11-01
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-23
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton Zhitong Certified Public Accountants LLP, Beijing, ChinaPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $953K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$32.9M-$2.5M-$4.0M$41.6MNo debt tags$108.1M10-Q 2026-11-06
Q2 2026
2026-06-30
$29.1M-$14.3M-$16.7M$43.3MNo debt tags$107.9M10-Q 2026-08-07
Q1 2026
2026-03-31
$22.5M-$18.6M$3.2M$37.5MNo debt tags$108.5M10-Q 2026-05-08
Q4 2025
2025-12-31
$23.6M-$1.3M$11.2M$49.2MNo debt tags$108.1M10-K 2026-03-13
Q3 2025
2025-09-30
$32.7M$1.9M-$2.6M$40.4MNo debt tags$112.4M10-Q 2026-11-06
Q2 2025
2025-06-30
$29.7M-$2.2M-$7.5M$36.5MNo debt tags$105.2M10-Q 2026-08-07
Q1 2025
2025-03-31
$22.1M$4.9M-$129K$15.0MNo debt tags$100.6M10-Q 2026-05-08
Q4 2024
2024-12-31
$27.9M$598K-$2.8M$11.8MNo debt tags$105.8M10-K 2026-03-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-06-23
Latest annual report10-K2026-03-13
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-05-04

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.5%
1 month-35.8%
3 months-34.1%
Year to date-39.0%
1 year-46.7%
From 52-week high-50.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CBIOCrescent Biopharma Inc.$13.50-4.59%$525.1M
MNPRMonopar Therapeutics Inc.$71.97-0.04%$487.7M
INDPIndaptus Therapeutics Inc.$3.45+8.83%$529.9M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier